Mostrar el registro sencillo del ítem
dc.contributor.author | Aguado Garcia, Diana | |
dc.contributor.author | Olvera, Alex | |
dc.contributor.author | Brander, Christian | |
dc.contributor.author | Sanchez Merino, Victor | |
dc.contributor.author | Yuste, Eloisa | |
dc.date.accessioned | 2022-03-22T16:31:07Z | |
dc.date.available | 2022-03-22T16:31:07Z | |
dc.date.created | 2022-03-22 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12080/29442 | |
dc.description.abstract | The long-term storage stability of vaccines has a major impact on the roll-out and success of global immunization programs. For the Human Immunodeficiency Virus type 1 (HIV-1) virus-like particle (VLP) vaccine prototype evaluated here, nanoparticle tracking analysis (NTA), and enzymelinked immunoabsorbent assay (ELISA) results demonstrated a remarkable structural stability. VLPs maintained their integrity and the recognition of relevant B-cell epitopes for three months at 4 and ¿20 ¿C. Interestingly, most particles remained intact and preserved the recognition of relevant epitopes even after a week of storage at room temperature. Keywords: virus-like particles; HIV; vaccine; thermostability | es_ES |
dc.format | application/pdf | es_ES |
dc.language | eng | es_ES |
dc.rights | CC-BY | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.es | es_ES |
dc.title | Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.location | N/A | es_ES |